Cannabis potency: The need for global monitoring

Addiction

Volumn 111, Issue 2, 2016, Pages 376-377

  Freeman, T P ^a   Swift, W ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cannabidiol; Delta 9 tetrahydrocannabinol; Dependence; Drug policy; Monitoring; Potency; Psychosis

Indexed keywords

CANNABINOID; CANNABIS;

CANNABIS SMOKING; CHEMISTRY; HEALTH; HUMAN; INTERNATIONAL COOPERATION; STANDARDS;

CANNABINOIDS; CANNABIS; GLOBAL HEALTH; HUMANS; INTERNATIONAL COOPERATION; MARIJUANA SMOKING;

EID: 84954368960     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13207     Document Type: Letter

References (18)

1. Niesink R. J., Rigter S., Koeter M. W., Brunt T. M. Potency trends of Δ9-THC, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-2015. Addiction 2015; doi:10.1111/add.13082.
2. Pijlman F., Rigter S., Hoek J., Goldschmidt H., Niesink R. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict Biol 2005; 10: 171-80.
3. Morgan C. J., Curran H. V. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008; 192: 306-7.
4. Morgan C. J., Schafer G., Freeman T. P., Curran H. V. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 2010; 197: 285-90.
5. Englund A., Morrison P. D., Nottage J., Hague D., Kane F., Bonaccorso S., et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol (Oxf) 2013; 27: 19-27.
6. Hindocha C., Freeman T. P., Schafer G., Gardener C., Das R. K., Morgan C. J., et al. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol 2015; 25: 325-34.
7. Freeman T. P., Winstock A. R. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med 2015; 45: 3181-9.
8. Di Forti M., Marconi A., Carra E., Fraietta S., Trotta A., Bonomo M., et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2015; 2: 233-8.
9. Wisselink D., Kuijpers W., Mol A. Key Figures in Addiction Care 2013. Houten: Stichting Informatie Voorziening Zorg; 2014.
10. Hardwick S., King L. A. Home Office Cannabis Potency Study 2008. St Albans, UK: Home Office Scientific Development Branch; 2008.
11. Licata M., Verri P., Beduschi G. Delta9 THC content in illicit cannabis products over the period 1997-2004 (first four months). Ann Ist Super Sanita 2005; 41: 483-5.
12. Mehmedic Z., Chandra S., Slade D., Denham H., Foster S., Patel A. S., et al. Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 2010; 55: 1209-17.
13. Cascini F., Aiello C., di Tanna G. Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 2012; 5: 32.
14. McLaren J., Swift W., Dillon P., Allsop S. Cannabis potency and contamination: a review of the literature. Addiction 2008; 103: 1100-9.
15. Swift W., Wong A., Li K. M., Arnold J. C., McGregor I. S. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLOS ONE 2013; 8: e70052.
16. Coombes R. Cannabis regulation: high time for change? BMJ 2014; 348: g3382.
17. Home Office. Explanatory Note to the Misuse of Drugs Act 1971 (Amendment) Order 2008 (2008 No. 3130). London, UK: Home Office; 2008.
18. Sevigny E. L., Pacula R. L., Heaton P. The effects of medical marijuana laws on potency. Int J Drug Pol 2014; 25: 308-19.